leuprolide acetate

GPTKB entity

Statements (48)
Predicate Object
gptkbp:instance_of gptkb:item
gptkbp:bfsLayer 5
gptkbp:bfsParent gptkb:Eligard
gptkbp:activities Gn RH receptor agonist
gptkbp:approves gptkb:1985
gptkbp:brand gptkb:Lupron
gptkb:Eligard
Viadur
gptkbp:clinical_trial Phase III
gptkbp:contraindication pregnancy
breastfeeding
hypersensitivity to leuprolide
gptkbp:discovered_by gptkb:Dr._Richard_J._Ablin
gptkbp:dosage_form 11.25 mg every 3 months
22.5 mg every 6 months
3.75 mg monthly
45 mg every 12 months
gptkbp:excretion urine
https://www.w3.org/2000/01/rdf-schema#label leuprolide acetate
gptkbp:ingredients C59 H84 N16 O13 S
gptkbp:interacts_with anticoagulants
hormonal therapies
antidiabetic medications
gptkbp:is_atype_of L02 A E01
gptkbp:is_available_on injectable solution
implant
gptkbp:is_used_for gptkb:healthcare_organization
gptkb:endometriosis
precocious puberty
uterine fibroids
gptkbp:lifespan 3 hours
gptkbp:manager intramuscular injection
subcutaneous injection
gptkbp:metabolism liver
gptkbp:pharmacokinetics long-acting
gptkbp:scholarships avoid alcohol
report any unusual bleeding
monitor for signs of adrenal insufficiency
discuss fertility preservation options
maintain regular follow-up appointments
gptkbp:side_effect fatigue
weight gain
mood changes
hot flashes
decreased libido
gptkbp:storage room temperature
protected from light
gptkbp:type_of 74381-53-6